Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IR 902 - Immune Response BioPharma

Drug Profile

IR 902 - Immune Response BioPharma

Alternative Names: AI 208; IR-208; Multiple sclerosis vaccine - Immune Response BioPharma; NeuroVax; V beta 17

Latest Information Update: 17 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immune Response Corporation
  • Developer Immune Response BioPharma; Orchestra Therapeutics
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple sclerosis
  • New Molecular Entity No
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Phase II Multiple sclerosis

Most Recent Events

  • 17 Sep 2018 IR 902 is available on expanded access (Immune Response BioPharma pipeline, September 2018)
  • 12 Aug 2015 Phase-II development for Multiple sclerosis is ongoing in USA
  • 06 Jan 2015 IR 902 is available for licensing as of 06 January 2015 www.immuneresponsebiopharma.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top